Blackstone Inc
AXSM icon

Blackstone Inc’s Axsome Therapeutics AXSM Stock Holding History

Blackstone Inc’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.14M Hold
24,500
– – 0.02% 137
2025
Q4 		$4.47M Sell
24,500
-115,500
-83% -$16.1M 0.02% 124
2025
Q3 		$17M Hold
140,000
– – 0.07% 81
2025
Q2 		$14.6M Buy
+140,000
New +$14.8M 0.06% 75

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Blackstone Inc's AXSM Position: Q1 2026 in Review

Blackstone Inc held its Axsome Therapeutics (AXSM) position steady in Q1 2026 at 24,500 shares worth $4.14M. The position accounts for 0.02% of the portfolio, ranked #137.

Blackstone Inc first reported a position in AXSM in Q2 2025 and has held it in 4 quarters since. The position peaked at $17M in Q3 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Blackstone Inc held 24,500 shares of Axsome Therapeutics worth $4.14M as of Q1 2026.
  • Blackstone Inc left its Axsome Therapeutics share count unchanged in Q1 2026.
  • Axsome Therapeutics made up 0.02% of Blackstone Inc's portfolio in Q1 2026, its #137 holding.
  • Blackstone Inc first reported a position in Axsome Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Blackstone Inc's Axsome Therapeutics position peaked at $17M in Q3 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Blackstone Inc's 13F filing for Q1 2026, filed 15 May 2026.